Orphan Drug Designation Expanded for Mobius Therapeutics’ Mitosol

November 3, 2017: By Jon Swedien

download (1)

Mobius Therapeutics announced Oct. 31 that the orphan drug designation for Mitosol has been changed to read: “treatment of refractory glaucoma as an adjunct to surgery.”

Mitosol is an ophthalmic reformulation of mitomycin C for use in glaucoma surgery. The new designation lays the groundwork for Mobius to pursue an expanded indication for Mitosol that would include refractory glaucoma surgery.

The new designation qualifies Mobius for a research and development tax credit and a waiver of its prescription drug user fee when it seeks an expanded designation, said Ed Timm, president of Mobius.

Ultimately, Mobius would like to pursue an expanded indication for Mitosol that would cover ab interno glaucoma surgery, Timm said. Ab interno glaucoma surgery includes minimally invasive glaucoma surgeries (MIGS). Mitosol is currently indicated as an adjunct to ab externo glaucoma surgery.

“New MIGS procedures, typified by the XEN Gel Stent, have relied upon Mitosol as a companion drug during pivotal clinical trials,” Timm said.

InnFocus, now part of Santen, has also used Mitosol in clinical trials for its MicroShunt MIGS device, Timm said.

St. Louis-based Mobius is a commercial stage venture focused upon perioperative sterile injectables used in ophthalmic surgery.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023